Clinical Trials at Huntsman Cancer Institute, University of Utah
As of August 2026, 33 paid clinical trials are recruiting at Huntsman Cancer Institute, University of Utah in Salt Lake City, Utah. Active studies at this site cover conditions such as Breast Cancer, Acute Myeloid Leukemia and Multiple Myeloma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
33 clinical trials at Huntsman Cancer Institute, University of Utah
·Clear filters·A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ivosidenib as Post-HSCT Maintenance for AML
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Common conditions studied in Salt Lake City
- Breast Cancer (20 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Multiple Myeloma (13 active studies)
- Advanced Solid Tumor (12 active studies)
- Obesity (11 active studies)
- Heart Failure (10 active studies)
Leading research sponsors in Salt Lake City
- University of Utah
- National Cancer Institute (NCI)
- Novartis Pharmaceuticals
- VA Office of Research and Development
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Salt Lake City?
There are approximately 943 recruiting clinical trials in Salt Lake City, Utah listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Salt Lake City pay participants?
Most recruiting trials in Salt Lake City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Salt Lake City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Salt Lake City?
The most common conditions under active study in Salt Lake City include Breast Cancer (20), Acute Myeloid Leukemia (13), Multiple Myeloma (13), Advanced Solid Tumor (12), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Salt Lake City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Salt Lake City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Salt Lake City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Salt Lake City?
Recruiting research sites in Salt Lake City include University of Utah, Huntsman Cancer Institute/University of Utah, Primary Children's Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Salt Lake City right now?
The largest active categories in Salt Lake City are Cancer & tumors (299), Neurology & pain (74), Cardiovascular (61). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.